干旱区生态环境知识资源中心(Arid): The possibilities of using levosimendan in medical preparation to Coronary Artery Bypass Grafting in coronary artery disease patients with low left ventricular ejection fraction

Arid

DOI	10.26442/00403660.2020.01.000492
	The possibilities of using levosimendan in medical preparation to Coronary Artery Bypass Grafting in coronary artery disease patients with low left ventricular ejection fraction
	Gazizova, V. P.; Vlasova, E. E.; Dzybinskaya, E., V; Gramovich, V. V.; Stukalova, O., V; Shiryaev, A. A.; Akchurin, R. S.
通讯作者	Gazizova, V. P.
来源期刊	TERAPEVTICHESKII ARKHIV
ISSN	0040-3660
EISSN	2309-5342
出版年	2020
卷号	92 期号:1 页码:43-48
英文摘要	Aim: to work out an approach of preoperative drug preparation for CAD patients with low LVEF and varying degrees of compensation for CHF, to study the possibility of using levosimendan (L) in this preparation. Materials and methods. We studied 82 patients with severe angina pectoris, multivascular coronary disease, extensive postinfarction zone, LVEF <= 35%, chronic heart failure and proven viable myocardium, which performed CABG. All patients received long-term standard CHF therapy before surgery: loop diuretic, ACF/ARA, beta-blocker, aldosterone antagonist. In the first, retrospective part of the study (39 pts), it was determined which factors could be associated with perioperative AHI-. In the second, prospective part (43 pts), the course of the operation and the early postoperative period in patients with compensated and uncompensated heart failure were compared; uncompensated pts received L 2 days before surgery in addition to standard therapy. The third, retro-prospective part of the study (37 pts) was the assessment of operation outcome in patients only with uncompensated pre-operative CHF, but with different preoperative drug preparation. Results. Statistically significant direct influence on the perioperative AHF development was provided by the combined clinical sign - venous pulmonary congestion+orthopnea (p<0.01). Patients with this sign presence, i.e. with uncompensated CHF, were infused with L before surgery; in this case the operation outcomes and the early postoperative period were similar to those in patients initially compensated; the only significantly different parameter was the Vasoactive Inotropic Score (VIS) at the end of the surgery (p=0.03). The effect of L was confirmed in the analysis of patients only with uncompensated CHF: those receiving L had significantly (p<0.05) lower VIS, inotropic support duration, time spent in ICU arid hospital stay. Conclusion. For CABG candidates with low LVEF and uncompensated CHF preoperative use of levosimendan is advisable; it improves the operation outcome and the course of the early postoperative period.
英文关键词	heart failure low cardiac output syndrome coronary bypass surgery levosimendan Vasoactive Inotropic Score
类型	Article
语种	俄语
国家	Russia
开放获取类型	gold
收录类别	SCI-E
WOS记录号	WOS:000504821100007
WOS关键词	CARDIAC-OUTPUT SYNDROME ; ADVANCED HEART-FAILURE ; SURGERY ; DOBUTAMINE ; SURVIVAL
WOS类目	Medicine, General & Internal
WOS研究方向	General & Internal Medicine
EI主题词	2020-01-01
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/312042
作者单位	AL Myasnikov Inst Cardiol, Natl Med Res Ctr Cardiol, Moscow, Russia
推荐引用方式 GB/T 7714	Gazizova, V. P.,Vlasova, E. E.,Dzybinskaya, E., V,et al. The possibilities of using levosimendan in medical preparation to Coronary Artery Bypass Grafting in coronary artery disease patients with low left ventricular ejection fraction[J],2020,92(1):43-48.
APA	Gazizova, V. P..,Vlasova, E. E..,Dzybinskaya, E., V.,Gramovich, V. V..,Stukalova, O., V.,...&Akchurin, R. S..(2020).The possibilities of using levosimendan in medical preparation to Coronary Artery Bypass Grafting in coronary artery disease patients with low left ventricular ejection fraction.TERAPEVTICHESKII ARKHIV,92(1),43-48.
MLA	Gazizova, V. P.,et al."The possibilities of using levosimendan in medical preparation to Coronary Artery Bypass Grafting in coronary artery disease patients with low left ventricular ejection fraction".TERAPEVTICHESKII ARKHIV 92.1(2020):43-48.